Advancements in Gene Therapy for Rare Genetic Disorders
DOI:
https://doi.org/10.36676/ssjmra.v1.i1.02Keywords:
Gene Therapy, Rare Genetic Disorders, Precision Medicine, Genetic Anomalies, Viral VectorsAbstract
Thanks to the tremendous advancements in gene therapy in the past few years, patients with rare genetic diseases now have a new reason to hope. gives a brief synopsis of current advances in gene therapy for different diseases. Rare hereditary disorders, which impact a tiny fraction of the population but render individuals extremely vulnerable, are typically caused by errors in a single gene. Prior to recently, doctors could only alleviate the symptoms of these conditions; they couldn't fix the underlying genetic defects that brought them on. However, a new era of precision medicine had begun with the advent of gene therapy, which would forever change the approach to treating uncommon diseases. Recent advances in gene therapy have showed hope as a means of treating or alleviating uncommon ailments resulting from genetic abnormalities. These innovations have been developed using state-of-the-art methods such as viral vectors, RNA-based treatments, and CRISPR-Cas9 gene editing. Trials have shown that these techniques have the potential to be therapeutically useful. Participants in these studies came from all walks of life and suffered from uncommon genetic illnesses.
References
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., ... & Sahenk, Z. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713-1722.
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E., Samelson-Jones, B. J., Ducore, J., ... & Sullivan, L. M. (2017). Hemophilia B gene therapy with a high-specific-activity factor IX variant. New England Journal of Medicine, 377(23), 2215-2227.
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z. F., Tillman, A., ... & Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet, 390(10097), 849-860.
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Zhang, F., Adams, S., ... & Fairbanks, L. D. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Science Translational Medicine, 3(97), 97ra79.
Matzner, U., Faust, N., Baisantry, A., Simon, E., & Henkel, B. (2016). Gene therapy for metachromatic leukodystrophy: a comprehensive study shows no therapeutic benefit of AAV1-Lamp2. Human Gene Therapy, 27(10), 772-779.
Ribeil, J. A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., ... & Cavazzana, M. (2017). Gene therapy in a patient with sickle cell disease. New England Journal of Medicine, 376(9), 848-855.
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E., Ribeil, J. A., Hongeng, S., ... & Gray, J. T. (2018). Gene therapy in patients with transfusion-dependent β-thalassemia. New England Journal of Medicine, 378(16), 1479-1493.
Burté, F., Carelli, V., Chinnery, P. F., & Yu-Wai-Man, P. (2015). Disturbed mitochondrial dynamics and neurodegenerative disorders. Nature Reviews Neurology, 11(1), 11-24.
FDA. (2020). Advancing Health through Innovation: 2020 New Drug Therapy Approvals. [Report]. U.S. Food and Drug Administration.
European Medicines Agency (EMA). (2021). Gene Therapy in the European Union: Overview and Guidelines. [Report]. European Medicines Agency.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Shodh Sagar Journal for Medical Research Advancement
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.